Aclaris Therapeutics, Inc. insider trading
Every open-market purchase and sale by Aclaris Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Aclaris Therapeutics, Inc.’s insiders pay?
From October 16, 2015 to April 27, 2026, 21 insiders reported 29 open-market purchases and 22 sales not made under a pre-set plan in Aclaris Therapeutics, Inc. Twelve months after each purchase was reported, the shares were −49.4% against the S&P 500 on average (median −74.8%), over 20 purchases with a full year of prices; 30% beat the index. After sales, the shares moved −44.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on October 19, 2015 into $236 by November 2, 2026, −28.9% a year. It held shares 46% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $25,434 (+8.8% a year), and held throughout $44,495 (+14.5%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% owner | 7 | — | — | 1 | — | April 27, 2026 |
| Ruffo Frank | Chief Financial Officer | 2 | −76.0% (2) | 0% | 3 | −20.5% (3) | March 14, 2022 |
| Walker Neal | President and CEO | 1 | −74.8% (1) | 0% | 4 | −42.3% (4) | March 3, 2023 |
| Ra Capital Healthcare Fund LP | 10% owner | 4 | +29.9% (4) | 75% | 0 | — | February 24, 2016 |
| Tullman Stephen A. | Director | 4 | −91.1% (4) | 0% | 0 | — | October 5, 2018 |
| Kolchinsky Peter | 10% owner | 3 | +34.0% (3) | 100% | 0 | — | January 13, 2016 |
| Mehra Anand | Director | 2 | −100.5% (1) | 0% | 1 | −40.4% (1) | November 20, 2024 |
| Monahan Joseph | Chief Scientific Officer | 0 | — | — | 3 | −61.2% (3) | March 3, 2023 |
| Balthaser Kevin | Chief Financial Officer | 1 | −109.9% (1) | 0% | 1 | −107.6% (1) | September 7, 2023 |
| Loerop James | Chief Business Officer | 1 | −110.6% (1) | 0% | 1 | −113.6% (1) | August 28, 2023 |
| Manion Douglas J. | Pres and CEO | 2 | −119.8% (2) | 0% | 0 | — | March 17, 2023 |
| Deerfield Management Company, L.P. | 10% owner | 0 | — | — | 1 | — | July 1, 2019 |
| Deerfield Partners, L.P. | 10% owner | 0 | — | — | 1 | — | June 25, 2019 |
| Flynn James E | 10% owner | 0 | — | — | 1 | −78.5% (1) | May 13, 2019 |
| Fmr LLC | 10% owner | 0 | — | — | 1 | −4.8% (1) | October 28, 2016 |
| Gordon David N. | Chief Medical Officer | 0 | — | — | 1 | +10.9% (1) | July 14, 2021 |
| Powell Andrew Kenneth William | Director | 1 | — | — | 0 | — | March 5, 2024 |
| Ra Capital Management, L.P. | 10% owner | 0 | — | — | 1 | −13.5% (1) | September 19, 2016 |
| Schiff Andrew N | Director | 1 | −57.5% (1) | 0% | 0 | — | August 16, 2017 |
| Vivo Ventures VII Affiliates Fund, L.P. | 10% owner | 0 | — | — | 1 | −53.7% (1) | March 2, 2017 |
| Vivo Ventures VII, LLC | 10% owner | 0 | — | — | 1 | −36.5% (1) | November 18, 2016 |
When several insiders traded Aclaris Therapeutics, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Aclaris Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 4 buying crowds with six months of prices, it averaged −37.3% against the index. After 4 selling crowds, −19.0%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| September 29, 2023 | 2 buying | −96.3% | −104.4% | −117.6% |
| March 31, 2023 | 4 selling | +20.6% | −24.9% | −113.3% |
| March 31, 2022 | 3 selling | −4.6% | +11.5% | −42.5% |
| June 30, 2021 | 3 selling | +0.7% | −29.7% | −9.9% |
| October 31, 2018 | 2 buying | −43.6% | −53.8% | −99.5% |
| April 30, 2018 | 3 buying | −12.0% | −33.2% | −77.9% |
| November 30, 2016 | 3 selling | −1.5% | −33.1% | −43.5% |
| October 30, 2015 | 2 buying | +59.6% | +42.3% | +42.4% |